Toxicities from immunotherapy: From clinical trials to real-world clinical practice.

Toxicities from immunotherapy: From clinical trials to real-world clinical practice. Med Clin (Barc). 2020 Aug 28;: Authors: Riveiro-Barciela M, Trallero-Araguás E, Martínez-Valle F, Vall d’Hebrón Group for the study of Immunotherapy immune-related adverse events, Vall d’Hebrón Committee for management of Immunotherapy immune-related adverse events Abstract In recent years, immunotherapy has become an important pillar of cancer treatment, with high response rates regardless of tumour histology or baseline mutations. However, immune activation associated with check-point inhibitors is not selective and a large variety of immune-related adverse events have been associated with anti-PD1, anti-PD-1/L-1 and anti-CTLA-4 agents. Though diagnosis and treatment of these toxicities have been established according to the recommendations from clinical trials and in line with the autoimmune disorders that they mimic, increasing real-world data is coming up showing that these adverse events may have differential characteristics and management, especially in terms of the use of corticoids, second-line treatments, salvage therapy for life-threatening cases and reintroduction of immunotherapy. Herein we present a comprehensive review of current recommendations and real-world data on the main immune-related adverse events of immunotherapy. PMID: 32868034 [PubMed - as supplied by publisher]
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research